Tuesday - May 6, 2025
NASHVILLE, Tenn. / Jul 25, 2024 / Business Wire / Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it will report its financial results for the second quarter ended June 30, 2024, on Wednesday, August 7, 2024, after the market close. The Company will also post its second quarter Letter to Stockholders to the “Investors” section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Thursday, August 8, 2024, to discuss the results and provide a business update.
Conference Call Information
Participants can access the live conference call via webcast on the “Investors” page of Harrow’s website. To participate via telephone, please register in advance using this link. Upon registration, all telephone participants will receive a confirmation email with detailed instructions, including a unique dial-in number and PIN, for accessing the call. A replay of the conference call and webcast will be archived on the Company’s website for one year.
About Harrow
Harrow, Inc. (Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the North American market. Harrow helps eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of patients each year. For more information about Harrow, please visit harrow.com.
Last Trade: | US$24.73 |
Daily Change: | -1.11 -4.30 |
Daily Volume: | 378,123 |
Market Cap: | US$880.640M |
March 24, 2025 March 17, 2025 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load